Ulcerative colitis: COMMAND Study (Risankizumab)

This study focuses on the drug risankizumab. It examines various phases, including a 52-week maintenance phase and open-label extensions, to assess safety and efficacy in patients who have previously responded to risankizumab. For patients who benefit from the treatment, there is the option of continuous therapy.